CapsoVision Announces $14 Million Private Placement Financing

Rhea-AI Summary

CapsoVision (NASDAQ: CV) closed a $14.0 million private placement on March 16, 2026, selling 2,867,089 shares at $4.883 per share (5% discount to the March 16 close).

Net proceeds will fund sales, R&D, G&A and working capital. Preliminary Q4 revenue was $3.9M, full-year 2025 revenue $13.6M, and cash and investments were approximately $10.1M as of December 31, 2025. Registration rights require a resale registration statement within 90 days; full audited results and a webcast are scheduled for March 26, 2026.

Positive

• Private placement raised $14.0 million gross proceeds
• Preliminary full-year 2025 revenue of $13.6 million
• Preliminary Q4 2025 revenue of $3.9 million
• Cash, cash equivalents and investments of approximately $10.1 million at year-end

Negative

• Issued 2,867,089 shares, creating shareholder dilution
• Shares sold at $4.883 per share, a 5% discount to the March 16 close
• Shares are unregistered and resale is restricted pending registration within 90 days

News Market Reaction – CV

+11.17%

22 alerts

+11.17% News Effect

+25.9% Peak in 1 hr 35 min

+$35M Valuation Impact

$344M Market Cap

1.1x Rel. Volume

On the day this news was published, CV gained 11.17%, reflecting a significant positive market reaction. Argus tracked a peak move of +25.9% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $35M to the company's valuation, bringing the market cap to $344M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Private placement size: $14 million Shares issued: 2,867,089 shares Offering price: $4.883 per share +5 more

8 metrics

Private placement size $14 million Gross proceeds from March 16, 2026 private placement

Shares issued 2,867,089 shares Common stock sold in March 16, 2026 private placement

Offering price $4.883 per share Price per share in private placement

Discount to market 5% discount Discount to March 16, 2026 closing price

Q4 2025 revenue $3.9 million Preliminary, unaudited fourth quarter 2025 revenue

Full year 2025 revenue $13.6 million Preliminary, unaudited full year 2025 revenue

Cash & equivalents $10.1 million Preliminary cash, equivalents, restricted cash and investments as of Dec 31, 2025

Registration deadline 90 days Timeline to file resale registration statement after closing

Market Reality Check

Price: $8.18 Vol: Volume 491,262 is 1.62x t...

high vol

$8.18 Last Close

Volume Volume 491,262 is 1.62x the 20-day average of 303,396, indicating elevated trading interest ahead of/around this financing and prelim results. high

Technical Shares at $6.18 are trading above the $5.59 200-day MA but remain 59.79% below the 52-week high, and 79.96% above the 52-week low.

Peers on Argus

CV gained 13.19% with active volume, while only one close peer (CVRX) appeared i...

1 Up

CV gained 13.19% with active volume, while only one close peer (CVRX) appeared in momentum scanning, up modestly and without related news. Other peers showed mixed moves, suggesting today’s action is primarily CV-specific rather than a broad Medical Devices shift.

Historical Context

5 past events · Latest: Mar 12 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Earnings date notice	Neutral	+3.0%	Announcement of timing for Q4 and full-year 2025 earnings release and call.
Mar 09	Investor conference	Neutral	+1.8%	Participation in ROTH conference with fireside chat and 1x1 investor meetings.
Dec 29	Regulatory submission	Positive	+7.0%	510(k) submission for AI-assisted reading module in CapsoCam Plus system.
Nov 20	Investor conference	Neutral	-1.9%	Announcement of participation in Benchmark one-on-one investor conference.
Nov 13	Earnings results	Neutral	-9.7%	Q3 2025 financial results with revenue growth but continued losses and IPO context.

Pattern Detected

Across five prior news events, three were followed by positive 24-hour moves and two by declines, indicating mixed but slightly positive reaction to company news.

Recent Company History

Recent updates show a mix of operational and investor-relations milestones. In Nov 2025, Q3 2025 results highlighted revenue growth but triggered a -9.7% reaction, while an AI-related 510(k) submission on Dec 29, 2025 saw shares rise 6.99%. Conference and event announcements in late 2025 and early 2026 produced modest single‑digit moves. Against this backdrop, the new $14 million private placement plus preliminary 2025 revenue adds fresh capital and visibility ahead of the scheduled Mar 26, 2026 earnings release.

Market Pulse Summary

The stock surged +11.2% in the session following this news. A strong positive reaction aligns with a...

Analysis

The stock surged +11.2% in the session following this news. A strong positive reaction aligns with a capital-raising event that added $14 million of gross proceeds alongside preliminary 2025 revenue figures of $3.9 million for Q4 and $13.6 million for the year. Historically, some product and regulatory updates have driven gains, while certain earnings releases saw selling. Investors assessing sustainability often watch how new cash affects runway and execution against upcoming catalysts such as the scheduled Mar 26, 2026 earnings release.

Key Terms

private placement, accredited investors, securities purchase agreement, section 4(a)(2), +3 more

7 terms

private placement financial

"announced the closing of a $14 million private placement in public equity financing"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

accredited investors financial

"entered into by the Company with selected accredited investors on March 16, 2026"

Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.

securities purchase agreement financial

"pursuant to a securities purchase agreement entered into by the Company"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

section 4(a)(2) regulatory

"in reliance on Section 4(a)(2) of the Securities Act and Rule 506"

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

regulation d regulatory

"Rule 506 of Regulation D promulgated under the Securities Act"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

registration statement regulatory

"agreed to file a registration statement with the SEC covering the resale"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

registration rights agreement financial

"Pursuant to a registration rights agreement with such investors, the Company has agreed"

A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.

AI-generated analysis. Not financial advice.

Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results

SARATOGA, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (the “Company”) (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the closing of a $14 million private placement in public equity financing (the “Private Placement”) pursuant to a securities purchase agreement entered into by the Company with selected accredited investors on March 16, 2026 for such investors to purchase shares (the “Shares”) of common stock of the Company.

Pursuant to the securities purchase agreement, the Company has agreed to sell 2,867,089 shares of common stock of the Company, with par value $0.001 per share, at $4.883 per share, which represents a 5% discount to the March 16th closing price, as per the terms of the agreement. The closing occurred on March 16, 2026, with approximately $14 million aggregate gross proceeds. The Company expects to use the net proceeds from the Private Placement for general corporate purposes, including sales and marketing, research and development activities, general and administrative matters, and working capital.

The offer and sale of the Shares in the Private Placement were made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws, and are being issued and sold in reliance on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act. Accordingly, the Shares may not be re-offered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Shares were offered only to accredited investors. Pursuant to a registration rights agreement with such investors, the Company has agreed to file a registration statement with the SEC covering the resale of the Shares within 90 days after the closing of the Private Placement. The Benchmark Company, LLC and Roth Capital Partners acted as financial advisors for the transaction.

“The participation of both new and existing investors in this financing underscores confidence in our platform and long-term opportunity,” said Johnny Wang, President and Chief Executive Officer. “We intend to deploy the proceeds toward continued product innovation and advancement of our pipeline, including CapsoCam Colon, CapsoCam UGI, and enhanced AI capabilities. We remain committed to disciplined execution and delivering sustainable, long-term value for our shareholders.”

Preliminary, Unaudited Fourth Quarter and Full Year Financial Results

CapsoVision also announced today preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025:

• Fourth quarter 2025 revenue is $3.9 million
• Full year 2025 revenue is $13.6 million
• As of December, 31, 2025, the Company had preliminary cash, cash equivalents, restricted cash and investments of approximately $10.1 million.
  

As previously announced, CapsoVision will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after the close of market. The Company will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.

About CapsoVision

CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expected”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “estimates”, “committed”, “will”, “should”, “could”, “would” or “may” and other words of similar meaning. Examples of these forward-looking statements include, but are not limited to, expectations regarding the Private Placement, including the Company’s use of proceeds from the Private Placement and registration of the Shares being issued and sold in the Private Placement, as well as statements concerning possible or assumed future results of operations and financial position, including the Company’s expectations regarding the Company’s product and clinical development efforts, the timing and receipt of regulatory submissions and approvals, the Company’s plans, strategies and timing for its pipeline development (including plans to address future indications in terms of new GI pathologies, patient enrollment in support of new generation colon capsule, and expanded patient populations and related timing of these efforts) and the success of the Company’s plans and strategies. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties, including those beyond the Company’s control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market conditions, the Company’s financial condition and the availability of cash, the failure to receive regulatory clearance and the failure to adapt the Company’s products for new indications. These and other risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s prospectus filed on July 3, 2025 with the SEC, as part of the Company’s Registration Statement on Form S-1 (File No. 333-287148), and the Company’s most recent Form 10-Q. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as required by law.

Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com

Media Contact
Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231

FAQ

What did CapsoVision (CV) announce on March 20, 2026 about financing?

CapsoVision announced a closed $14.0 million private placement completed March 16, 2026. According to the company, 2,867,089 shares were sold at $4.883 per share (a 5% discount), with proceeds to support operations, R&D, sales, and working capital.

How many shares did CapsoVision (CV) issue and at what price in the private placement?

CapsoVision issued 2,867,089 shares at $4.883 per share in the March 16, 2026 closing. According to the company, that per-share price represented a 5% discount to the March 16 closing market price.

What will CapsoVision (CV) use the $14 million proceeds for?

The company will use net proceeds for general corporate purposes including sales, research and development, general and administrative expenses, and working capital. According to the company, deployment prioritizes product innovation and pipeline advancement.

When will CapsoVision (CV) release full 2025 results and how can investors access the update?

CapsoVision will release fourth-quarter and full-year 2025 results after market close on March 26, 2026, with a conference call and live webcast at 1:30 pm PT. According to the company, the call will provide a corporate update and financial details.

What were CapsoVision's preliminary financials for Q4 and full-year 2025?

Preliminary results show Q4 2025 revenue of $3.9 million and full-year 2025 revenue of $13.6 million. According to the company, cash and investments totaled approximately $10.1 million as of December 31, 2025.